After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
Senseonics
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
Senseonics down on tightened guidance — but it hits milestone on 365-day implantable CGM
Senseonics (NYSE American: SENS) reported a third-quarter revenue beat, but its stock took a hit amid tightened full-year revenue guidance. The Germantown, Maryland–based maker of implantable continuous glucose management systems lost $60.4 million, or 13¢ per share, off $4.6 million in revenue for the quarter ended Sept. 30, 2022. In contrast, Senseonics saw a profit […]
Ascensia Diabetes integrates its Eversense CGM with Apple Health
Ascensia Diabetes Care announced today that it has updated its Eversense Continuous Glucose Monitoring system app to integrate with Apple Health. The Parsippany, N.J.-based company makes the Contour Blood Glucose Monitoring (BGM) system and distributes Senseonics’ Eversense CGM system. The new Apple Health integration will allow people with diabetes using Senseonics’ Eversense CGM systems to […]
Ascensia, Senseonics partner with Nurse Practitioner Group on CGM insertion options
Senseonics (NYSE:SENS) and Ascensia Diabetes Care launched a collaboration with the Nurse Practitioner Group (NPG) today. NPG offers multidisciplinary health services and medical staffing solutions. The collaboration aims to broaden access to the Eversense E3 continuous glucose monitor (CGM) system. Senseonics developed Eversense E3 and Ascensia distributes the system as the company’s partner. The collaboration […]
Ascensia completes Senseonics Eversense E3 European launch
Ascensia Diabetes Care announced that it successfully completed its initial European launch for the Senseonics (NYSE:SENS) Eversense E3. Eversense E3 represents Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 can be used for up to six months (180 days). This doubles the wear time of its previous-generation CGM. Ascensia said in a news release […]
Senseonics offers equity grants under inducement plan
Senseonics (NYSE:SENS) announced today that it granted six new non-executive employees stock options under an inducement plan. Germantown, Maryland-based Senseonics granted the employees non-qualified stock options. The options allow them to purchase an aggregate of 78,000 shares of the company’s common stock. It represents an inducement for such employees to join the company, according to a […]
Senseonics CFO is leaving
Senseonics (NYSE:SENS) announced that its chief financial officer, Nick Tressler, is transitioning from his position at the CMG company.. Tressler’s transition is effective as of yesterday, Sept. 1, 2022. Senseonics selected VP of Finance, Rick Sullivan, to succeed Tressler as CFO. In an effort to ensure an orderly change, Tressler will remain with the company […]
Senseonics stock is up as it sticks by revenue guidance
Senseonics (NYSE:SENS) shares were up slightly today on second-quarter results that came up shy of the consensus forecast. The Germantown, Maryland-based continuous glucose monitoring technology developer yesterday evening posted profits of $103.9 million, or 22¢ per share, on sales of $3.7 million for the three months ended June 30, 2022, for a massive bottom-line gain […]
Anthem to provide coverage for Senseonics’ next-gen CGM
Senseonics (NYSE:SENS) announced today that Anthem is providing coverage for implantable continuous glucose monitoring (CGM). The coverage extends to the Eversense CGM system — including the recently launched next-generation Eversense E3 180-day CGM — meaning that Senseonics’ global commercial partner, Ascensia Diabetes Care, can introduce the CGM to more people living with diabetes. Germantown, Maryland-based […]
